Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Cash from Investing Activities (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Cash from Investing Activities for 13 consecutive years, with -$15.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 398.92% year-over-year to -$15.0 million, compared with a TTM value of $72.9 million through Dec 2025, up 410.35%, and an annual FY2025 reading of $72.9 million, up 410.35% over the prior year.
  • Cash from Investing Activities was -$15.0 million for Q4 2025 at Tandem Diabetes Care, down from $20.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $58.1 million in Q2 2025 and bottomed at -$76.8 million in Q4 2021.
  • Average Cash from Investing Activities over 5 years is -$9.5 million, with a median of -$5.6 million recorded in 2021.
  • The sharpest move saw Cash from Investing Activities plummeted 606.62% in 2023, then soared 1742.09% in 2025.
  • Year by year, Cash from Investing Activities stood at -$76.8 million in 2021, then surged by 146.57% to $35.8 million in 2022, then tumbled by 146.35% to -$16.6 million in 2023, then skyrocketed by 130.21% to $5.0 million in 2024, then crashed by 398.92% to -$15.0 million in 2025.
  • Business Quant data shows Cash from Investing Activities for TNDM at -$15.0 million in Q4 2025, $20.5 million in Q3 2025, and $58.1 million in Q2 2025.